Table 8.
Ongoing clinical trials assessing the efficacy of MET inhibitors in lung cancer.
| Inhibitor | NCT number | Phase | Population | Treatment | Estimated enrollment | Primary outcome | Status |
|---|---|---|---|---|---|---|---|
| Cabozantinib (XL184) | NCT01639508 | II | Group B includes MET amplification | Cabozantinib 60mg QD | 68 | ORR | Recruiting |
| NCT03911193 | II | Advanced lung cancer with MET mutations | Cabozantinib 60mg QD | 25 | ORR | Recruiting | |
| Tepotinib | NCT02864992(VISION) | II | Advanced NSCLC with METex14 or MET amplification | Tepotinib 500mg QD | 330 | ORR | Recruiting |
| NCT03940703(INSIGHT 2) | II | Locally advanced or metastatic NSCLC with MET amplification | 120 | DLTs and ORR | Recruiting | ||
| Capmatinib (INC280) | NCT03693339 | II | Advanced NSCLC with METex14 | Capmatinib 400 mg TID | 27 | ORR | Recruiting |
| NCT02414139 | II | Previously treated c-MET+ NSCLC | INC280 (capmatinib) | 368 | ORR | Recruiting | |
| NCT02750215 | II | Previously treated NSCLC with MET mutation | INC280 (capmatinib) | 20 | ORR | Active, not recruiting | |
| Telisotuzumab (ABBV-399) | NCT03539536 | II | Previously treated c-MET+ NSCLC | Telisotuzumab | 310 | ORR | Recruiting |
| Crizotinib | NCT04084717 | II | Advanced NSCLC with MET mutation | Crizotinib 250mg BID | 50 | ORR and PFS | Recruiting |
| Savolitinib | NCT03778229 | II | Advanced NSCLC with EGFRm+ MET+ | Savolitinib 300 mg or 600 mg QD | 192 | ORR | Recruiting |
| Rilotumumab (AMG-102) | NCT02154490 | II/III | S1400E Arm I: SCCA with HGF/c-MET positive | Rilotumumab IV and erlotinib daily | 10000 | PFS, ORR and OS | Active, not recruiting |
NSCLC, non-small cell lung cancer; MET, mesenchymal-epithelial transition factors; Ex, exon; Mut, mutation; QD, once daily; BID, twice daily; TID, third daily; ORR, objective response rate; OS, overall survival; PFS, progression free survival; DLT, dose limiting toxicity.